GM PHARMA is a global pharmaceutical company originating from Georgia, with medicines and food supplements manufactured in GMP-certified manufacturing plants in Western European countries (Germany, Greece, Spain, Switzerland, Italy, Sweden, Portugal) and in its own GMP-certified manufacturing plant in Georgia.

GM PHARMA's history dates back 25 years to the late '90s, following the Soviet Union's collapse, when Georgia faced a significant shortage of pharmaceutical products. This challenging period sparked the initiative to establish a global pharmaceutical company in Georgia, adhering to international standards. GM PHARMA introduced its first medication, Rifampicin capsules, in February 2000.

Celebrating its 25th anniversary, GM PHARMA now annually treats up to 14 million patients in Georgia and internationally.

From 2003 to 2007, the Company's products registered in the CIS countries.

In 2004, the quality assurance system of the Company was granted the Certificate ISO 9001:2000 in compliance with international standards by ISO. The Company undergoes the control audit every year since 2005, in compliance with the current version of ISO 9001 (Certification body TÜV SÜD Management Service GmbH, Germany):

In 2005, the Research and Development Laboratory (R&D) was established.

In 2014, 2017, 2018, 2020, and 2023, the company was inspected by Ukrainian Regulatory Inspection and was granted the certificate of compliance with GMP PIC/S, which confirms the Company's compliance with the current versions of regulatory documents harmonized with the Pharmaceutical Inspection Cooperation Scheme (PIC/S), EU directives and WHO requirements.

In 2018, a new certified Research and Development Laboratory was established in GM PHARMA, which includes Formulation Development and Analytical Development Laboratories.

In 2019 and 2023, the Company's Microbiological Control Laboratory was accredited to ISO 17025:2017/2018 and granted the status of an accredited laboratory by the Accreditation Centre – National Body of Accreditation.

In 2022 and 2023, GM PHARMA successfully passed EU GMP compliance audits conducted by the highly reputable European companies, reaffirming its adherence to international manufacturing standards (Pharmakon, Denmark – 2022; Heacon Service GmbH (pharma-audit group), Germany – 2023; Woodley BioReg, UK – 2023).

• Venotonics
• Cns & eye care
• Food supplements
• Cardiovascular
• Urogynaecology
• Gastroenterology
• Endocrinology
• Dermatology
• Anti-infectives
• Respiratory & allergy
• Nsaids
• Oncology

GM PHARMA employs more than 600 professionals, including those employed in its export countries. With more than 130 brands and 220 dosage forms in its portfolio, GM PHARMA holds one of the broadest product portfolios in the region, covering almost all dosage forms and therapeutic areas, including a wide range of food supplements.

More than 12 million patients are treated with GM PHARMA products in Georgia and the company's international export markets every year.

The company's future plans include investing in a greenfield construction project for a new plant to enhance manufacturing capacity in Oral Solid Dosage (OSD) products and introduce sterile products like liquid ampoules and vials, lyophilized vials, also establish production capacities in soft gels, oral liquids, and powders production.

Moreover, a higher emphasis is placed on manufacturing and in the search for drug products under a first-to-market strategy in Georgia and in the export markets of GM PHARMA.

GM PHARMA's solid dosage forms manufacturing site in Tbilisi, Georgia, is the largest pharmaceutical plant in the Caucasus region. The basic formulation processes currently carried out in the factory are: dispensing, blending, granulation, tableting, tablet coating, capsule filling, bottle filling, sachet filling and blister and bottle packaging, quality control.

GM PHARMA's manufacturing plant is equipped with modern machinery and laboratory equipment made by the world's leading companies: Gerteis, L.B. Bohle, Bosch, Fette, Uhlmann, Hüttlin, Ima, Servolift, Sartorius, Mettler Toledo, Skinetta, Enflex, Erweka, Millipore, BMT, Thermo Scientific, Panasonic, Shimadzu, Waters, Waldner, Rumed Weiss Technik, Agilent Technologies, Stilmas, Korsch, Guk, Volkman, Piab, Radwag, Belimed, etc.

The 55% of the company's annual turnover comes from its own manufacturing site in Tbilisi, while the 45% comes from the sales under GM PHARMA's trademark of imported products manufactured by GMP-certified manufacturers in various countries.

GM PHARMA has 150 Suppliers & CMOs in 40 Countries.

GM PHARMA has experience in joint licensing projects together with the world's leading pharmaceutical companies:

• F. Hoffmann-La Roche (Switzerland): Packing of imported finished dosage form of pegylated interferon for the regional market (2013-2015).
• Lallemand Pharma (Switzerland): Packing of imported product ISMIGEN® for sales in Georgia and export countries (ongoing project launched in 2010). Importing and promotion of Healsea® BABYKIDS & Healsea® CHRONIC for sales in Georgia and export countries (ongoing project launched in 2025).

The company has established joint ventures with world-renowned pharmaceutical companies, such as: Medichem, Cinfa, Reig Jofre & Kern Pharma (Spain), Novonesis (Denmark), Basi (Portugal), Ibrahim Etem – Menarini (Turkey), Elpen & Pharos (Greece), WeltPharma (Germany) and others.

In February 2022, GM PHARMA successfully completed the international training audit conducted by the European GMP Inspectors of the Danish company Pharmakon, a partner of the World Health Organization (WHO), by which it was once again confirmed the compliance of the manufacturing site, laboratories, warehouse, equipment, utilities and quality management systems in general with the EU Good Manufacturing Practice (EU GMP) standards.

In 2023, GM PHARMA successfully passed the EU GMP EudraLex, Volume 4, Good Manufacturing Practice compliance audit, conducted by the pharma-audit group of the highly reputable German company Heacon Service GmbH (pharma-audit group).

In 2023, GM PHARMA also successfully passed the EU GMP compliance audit conducted by British experts from Woodley BioReg (UK), a leading regulatory consultancy firm specialising in pharmaceutical, biotechnology, and medical device regulatory affairs.

​GM PHARMA implements Corporate Social Responsibility (CSR) programs focused on improving public health and raising awareness. The company's CSR initiatives primarily involve supporting large-scale healthcare campaigns.

The company regularly joins global initiatives such as World Heart Day and World Hypertension Day. Under these campaigns, GM PHARMA finances the provision of free medical services in partner clinics. The public is offered necessary cardiological examinations, including electrocardiograms (ECG) and echocardiography, as well as free consultations with a cardiologist.

The company collaborates with leading medical specialists to create educational video materials. These videos are dedicated to raising public awareness about the risks, symptoms, and management methods of cardiovascular diseases. ​

GM PHARMA sponsors significant medical events, such as the Congress of the Society of Cardiologists.

• 2004 – "The Best Medium-sized Enterprise in Georgia" – awarded by the Georgian Chamber of Commerce and Industry (GCCI).

• 2011 – "Successful Manufacturer of Export Products" – the National Business Award "Mercury 2011" – was awarded by the Ministry of Economy and Sustainable Development and the National Investment Agency of Georgia.

• 2017- 2024 – "Leader of the Year" in Georgian Pharmaceutical Industry – awarded by Swiss Rating Agency and National Business Rating Union.^[1]